Kangmei Pharmaceutical Hits Day Low of CNY 1.51 Amid Price Pressure

Kangmei Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.18% to touch an intraday low of CNY 1.51. This performance reflects a broader trend of underperformance, as the company has seen a significant decrease of 23.62% over the past year, contrasting sharply with the China Shanghai Composite's gain of 20.36% during the same period. The company's financial metrics indicate ongoing challenges, with net profit for the latest quarter falling dramatically by 256.66% to CNY -3.8 million. Additionally, pre-tax profit has decreased by 78.51%, highlighting a concerning trend in profitability. Over the last five years, net sales have grown at a modest annual rate of 0.67%, while operating profit has increased by 14.07%. However, these figures suggest limited growth potential. Kangmei's return on equity stands at a low 0.17%, and the stock's price-to-book ratio is at 3.03, indicating a potentially expensive valuation. The company's market capitalization is CNY 22,053 million, placing it within the large-cap category in the pharmaceuticals and biotechnology industry.